Sellers Co., Ltd. (CEO Kim Seong-geun) announced that it will participate in the ‘6 International Advanced Medical Devices and Medical Industry Exhibition (KOAMEX 30)’, which will be held at EXCO in Daegu for three days from Friday, June 7th to Sunday, July 2nd.
Sellers is a bio venture company that has been developing new immune and metabolic anti-cancer drugs and companion diagnostics based on Tumor Associated Macrophage (TAM).
TAM is centrally involved in the resistance mechanism of cancer immunotherapy drugs within the tumor microenvironment and helps cancer growth by suppressing T cells and promoting cancer cell growth. Sellers, which is building a treatment strategy to respond to these TAMs, differentiates itself from its competitors by simultaneously handling antibodies and small molecule compounds to overcome the limitations of the existing pipeline.
At this exhibition, Sellers plans to introduce its tumor treatment antibodies, including ▲CLS-A1 ▲CLS-A2 ▲CLS-S3.
CLS-A1 is an antibody being developed to treat incurable tumors. It promotes the differentiation of macrophages into TAMs and exerts a counteracting effect on ‘CXCL16’, which contributes to the increase in tumor aggressiveness. Inhibiting CXCL1 with CLS-A16 can lower the cancer cell metabolism and growth rate to the level of single culture, and animal experiments have also demonstrated anticancer efficacy similar to that of the chemical anti-membrane drug ‘paclitaxel’ when administered alone.
The company explains that CLS-A1, which has completed IgG humanization and is undergoing a lead material optimization process, has better safety and tolerability than chemical anticancer drugs and can be used as a therapeutic antibody to replace existing drugs. In addition, significant clinical benefits can be expected, such as improving the immune environment of patients already undergoing chemotherapy treatment.
CLS-A2 is a treatment that responds to the biomarker ‘RANKL’, which differentiates osteoclast precursor cells into osteoclasts and activates osteoclasts to release tumorigenic factors. At the same time, Sellers is developing CLS-A16 as a dual antibody that simultaneously targets RANKL and CXCL2, focusing on the fact that CXCL16 stimulates osteoclast precursor cells that accelerate bone destruction.
CLS-S3, which will be presented together, functions to suppress MYC gene mutations commonly observed in most carcinomas. It is being developed as a small molecule compound that inhibits MYC protein expression at the transcription stage by inhibiting CDK7 protein, and cell-level experiments have confirmed that CLS-S3 effectively regulates MYC expression in cancer cells and promotes apoptosis at the same time. In addition, the official emphasized that it was confirmed to have excellent anti-cancer effects in animal tests on a triple-negative breast cancer (TNBC) model.
Sellers said, “Our company is currently focusing on developing antibodies and small molecule compounds to overcome the resistance mechanism of third-generation immunotherapy drugs. “We would like to propose treatment strategies and technologies based on this unique yet innovative mechanism to the related industry,” he said. “At the same time, we are also developing a companion diagnostic device using liquid biopsy. “It will also be of great significance in introducing the utility and leadership of this technology, which analyzes blood samples with a microfluidic chip to separate and identify immune cells by cluster in the tumor microenvironment,” he said, explaining the reason for participating in this exhibition.
Meanwhile, the main exhibition items of ‘KOAMEX 2023’ hosted by Daegu Metropolitan City and K-MEDI Hub are as follows. △Diagnostic and diagnostic devices such as scanners, measuring devices, and imaging devices △Clinical and inspection devices △Surgical and recycling devices △Hospital facilities and emergency equipment △Medical devices, parts, and services △Pharmaceutical devices △Medical services, SW